801306-55-8

Basic information

• Product Name: 1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-one
• Synonyms: 1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-one;1-[3-(trifluoromethyl)-2-pyridinyl]-4-Piperidinone
• CAS NO: 801306-55-8
• Molecular Formula: C11H11F3N2O
• Molecular Weight: 244.2130496
• Mol File: 801306-55-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-one(801306-55-8)
• EPA Substance Registry System: 1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-one(801306-55-8)

Safety Data

• Hazardous Substances Data: 801306-55-8(Hazardous Substances Data)

Usage

General Description

1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-one is a chemical compound with the molecular formula C12H12F3NO. It is a piperidinone derivative with a trifluoromethylpyridinyl group attached to the piperidine ring. 1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-one has potential biological activities and has been studied for its potential therapeutic applications. Additionally, it can be used as an intermediate in the synthesis of other pharmaceuticals and chemical compounds. The trifluoromethyl group in the pyridinyl ring contributes to the compound's unique properties and potential applications in the field of medicinal chemistry and drug discovery.

Upstream product

• 65753-47-1 2-chloro-3-trifluoromethyl-pyridine 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 801306-54-7 C₁₃H₁₅F₃N₂O₂ 

Relevant articles and documents

1,2-Diamino-ethane-substituted-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d] azepines as TRPV1 antagonists with improved properties

Based upon a previously reported lead compound 1, a series of 1,2-diamino-ethane-substituted-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepines were synthesized and evaluated for improved physiochemical and pharmacokinetic properties while maintaining TRPV1 antagonist activity. Structure-activity relationship studies directed toward improving the aqueous solubility (pH 2 and fasted-state simulated intestinal fluid (SIF)) and rat pharmacokinetics led to the discovery of compound 13. Aqueous solubility of compound 13 (pH 2 = >237 μg/mL and SIF = 11 μg/mL) was significantly improved over compound 1 (pH 2 = 5 μg/mL and SIF = 0.5 μg/mL). In addition, compound 13 afforded improved rat pharmacokinetics (CL = 0.7 L/kg/h) compared to compound 1 (CL = 3.1 L/kg/h). Compound 13 was orally bioavailable and afforded a significant reversal of carrageenan-induced thermal hyperalgesia at 5 and 30 mg/kg in rats.

AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, and R3, are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

AMIDE DERIVATIVE

An amide derivative represented by the formula (I) wherein A is a cycloalkyl group, an aryl group or a heteroaryl group, X is a nitrogen atom or CR17, Y is NRa, -(CRbRb')m- and the like, m is 0-4, and R1-R17 may be the same or different and each is a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, a formyl group, a hydroxyl group, an ammonium group, an alkyl group optionally having a substituent(s), ZR18 and the like, Z is -O-, -S(O)p-, -S(O)pO-, -NH-, -NR19- and the like, or R1 and R2 may in combination form a ring, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof is applied to pharmaceutical use such as anti-inflammatory and analgesic action and the like.